Share on StockTwits

Progenics Pharmaceuticals (NASDAQ:PGNX) will issue its Q114 quarterly earnings data on Friday, May 9th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $2.88 million for the quarter.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.19) by $0.05. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $1.48 million. During the same quarter last year, the company posted ($0.01) earnings per share. Progenics Pharmaceuticals’s revenue was down 66.3% compared to the same quarter last year. On average, analysts expect Progenics Pharmaceuticals to post $-0.37 EPS for the current fiscal year and $-0.49 EPS for the next fiscal year.

Progenics Pharmaceuticals (NASDAQ:PGNX) opened at 3.47 on Thursday. Progenics Pharmaceuticals has a one year low of $3.20 and a one year high of $7.45. The stock has a 50-day moving average of $3.83 and a 200-day moving average of $4.59. The company’s market cap is $241.4 million.

Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.